Ras and Rab Interactor 3 (RIN3) functions as a Guanine nucleotide Exchange Factor (GEF) for some members of the Rab family of small GTPase. By promoting the activation of Rab5, RIN3 plays an important role in regulating endocytosis and endocytic trafficking. In addition, RIN3 activates Ras, another small GTPase, that controls multiple signaling pathways to regulate cellular function. Increasing evidence suggests that dysregulation of RIN3 activity may contribute to the pathogenesis of several disease conditions ranging from Paget’s Disease of the Bone (PDB), Alzheimer’s Disease (AD), Chronic Obstructive Pulmonary Disease (COPD) and to obesity. Recent genome-wide association studies (GWAS) identified variants in the RIN3 gene to be linked with these disease conditions. Interestingly, some variants appear to be missense mutations in the functional domains of the RIN3 protein while most variants are located in the noncoding regions of the RIN3 gene, potentially altering its gene expression. However, neither the protein structure of RIN3 nor its exact function(s) (except for its GEF activity) has been fully defined. Furthermore, how the polymorphisms/variants contribute to disease pathogenesis remain to be understood. Herein, we examine, and review published studies in an attempt to provide a better understanding of the physiological function of RIN3; More importantly, we construct a framework linking the polymorphisms/variants of RIN3 to altered cell signaling and endocytic traffic, and to potential disease mechanism(s).

Keywords: RIN3, Rab5, endocytosis, trafficking, Alzheimer’s disease

THE RAS AND RAB INTERACTOR PROTEIN (RIN) FAMILY

RIN Proteins as the Guanine Nucleotide Exchange Factor for Rab5

The highly conserved RIN family that includes RIN1, RIN2, RIN3 and the RIN-like protein (RINL). All the RIN members (except RINL) are composed of five functional domains: a Src homology 2 (SH2) domain, a proline-rich domain (PRD), a RIN-homology (RH) domain, a VPS9 domain (vacuolar protein sorting-associated protein 9) and a Ras-association (RA) domain (Figure 1). The only difference among the RIN members lies in the number of PRDs contained; RIN1 has one, RIN2 has two, RIN3 has three, while RINL has none (Figure 1). In 1991, Colicelli and colleagues used a cDNA library to screen for possible interactor(s) that interfered with RAS function in Saccharomyces cerevisiae (Colicelli et al., 1991). They discovered that, although RIN1 and two other proteins bound to Ras, they did not suppress the activated form of Ras (Colicelli et al., 1991). Then in 1997, Rab Guanine Nucleotide Exchange Factor 1 (RabGEF1, also called Rabex5) and its yeast homolog Vps21p were identified by their preferential binding to Rab5 in its nucleotide-free state and by catalyzing the GDP/GTP exchange of Rab5 (Bucci et al., 1992; Hama et al.,
FIGURE 1 | Structure of the RIN protein family. Domain structures of individual RIN proteins. Functional domains with indicated residues are presented by frames. SH2, src homology 2; PRD: proline-rich domain; RH: Rin homology; VPS9: vacuolar protein sorting-associated protein 9; RA: Ras-association. The amino acid residues for each of these domains are marked.

FIGURE 2 | Expression profile of RIN family in normal human tissues. (A): RNA levels of individual RIN genes. Data comes from HPA RNA-seq normal tissues project (Fagerberg et al., 2014). (B): Protein expression level of RIN1/2/3. Data comes from the Human Protein Atlas (https://www.proteinatlas.org/).
The conversion of GDP-bound to GTP-bound form results in the activation of Rab5 that promotes endocytosis and endocytic traffic (Bucci et al., 1992; Xu et al., 2016). Thus, Rabex5 was the first guanine nucleotide exchange factor (GEF) identified for the small GTPase Rab5 (Horiiuchi et al., 1997). A detailed structural analysis of Rabex5 showed that it contained a Vps9 catalytic domain that was responsible for its GEF activity towards Rab5 (Hama et al., 1999). It was since suggested that any proteins that contained the same modularity and biochemical characteristic of the Vps9 domain may also function as a GEF to activate Rab5 (Hama et al., 1999). Based on these principles, RIN1 (Tall et al., 2001), RIN2 (Saito et al., 2002), RIN3 (Kajiho et al., 2003b; Kajiho et al., 2011) and RINL (Woller et al., 2011; Kajiho et al., 2012), were all identified and confirmed to function as GEFs to promote the activation of Rab5.

Expression Profiles
All three human RIN mRNA and proteins are widely expressed in human tissues (Figures 2A,B). However, the tissue distribution of RIN3 protein appears to be more selective than RIN1 and 2 (Janson et al., 2012) (Figure 2B). For the purpose of this review, we are mostly focused on RIN3. Human RIN3 gene is located on chromosome 14q32 and encodes a protein of 985 residues (Figure 1). The RIN3 mRNA is found at the highest levels in the hematopoietic system that includes bone marrow and lymphatic tissues (Uhlén et al., 2015) (Figure 2A). Relatively high expression of RIN3 mRNA is also seen in the nervous systems, the pulmonary and the male reproduction system (Figure 2A). In human tissues, RIN3 protein has been found to be mostly expressed in the peripheral blood cells and also in the brain, muscle, colon and mast cells (Kajiho et al., 2003b; Uhlén et al., 2015) (Figure 2B).

Domain Structure
The Role of VPS9 Domain
The Vps9 domain in human RIN3 (residues 724–864; Figure 1) is found in 18 other human proteins including Rabex5, other members of the RIN family and ALS2 (Amyotrophic Lateral Sclerosis Type 2) and in yeast Vps9p (Hama et al., 1999; Esters et al., 2001; Otomo et al., 2003). Anna Delprato and colleagues constructed a panel of 37 mammalian Rab GTPases and found that the helical bundle-VPS9 domain in Rabex5 showed activity in catalyzing the release of GDP from these Rab proteins. In particular, the Rabex5 VPS9 domain exhibited a potent GEF activity specific for Rab5, Rab21 and weak activity for Rab22, while showing no detectable activity for other Rab proteins (Delprato et al., 2004). Due to the presence of a VPS9 domain in RIN1, it was not surprising that RIN1 was shown to have strong GEF activity for Rab5A, Rab5B, Rab5C and Vps21p (Tall et al., 2001). Kajiho and colleagues employed elegant biochemical studies and demonstrated that RIN3 also promoted GTP binding of Rab31, another member of the Rab5 family (Kajiho et al., 2003b; Kajiho et al., 2011).

The VPS9 domain in the RIN family proteins is essential for their Rab5 GEF activity, as its deletion in RIN2 completely abolished its capability to bind Rab5 and to catalyze release of GDP (Saito et al., 2002). Furthermore, mutations of four residues (Asp 313, Pro 317, Tyr 354, and Thr 357) in the VPS9 domain of Rabex5 severely impaired its GEF activity for both Rab5 and Rab21 (Delprato et al., 2004). Similarly, double mutations in the respective VPS9 domain of RIN1 (D537A + P541A or Y577A + T580A), RIN2 (D696A + P700A or Y736A + T739A), RIN3 (D785A + P789A or Y825A + T828A) each led to significant reductions in their GEF activity. The Y825A + T828A mutations in RIN3 were especially effective for inhibiting its GEF activity (Kajiho et al., 2011). These findings establish the essential GEF function of VPS9 to activate Rab proteins.

The Role of the RH Domain
Although the VPS9 domain is necessary for RIN proteins to interact with and catalyze activation of Rab5, it is not sufficient to accomplish the task; the RH domain (residues 588–718 in RIN3) is also required for RIN3 interaction with Rab5 proteins. Using a yeast two hybrid system to study the impact of different domains of RIN2 on activation of Rab5, Saito et al., demonstrated that deletion of either the RH or the VPS9 domain resulted in a complete loss of interaction between Rab5 and RIN2 (Saito et al., 2002). This is further supported by a previous structural analysis showing that the Rabex5 VPS9 domain appeared to interact with its upstream helical bundle structure (~88 amino acids) (Delprato et al., 2004; Delprato and Lambright, 2007). Therefore, it is possible that a collaborative effect between the RH and VPS9 domains is necessary in recruiting and catalyzing activation of Rab5 proteins. In addition, when eight serine residues (523, 524, 530, 533, 535, 537, 583, 586) of the internal sequence between SH2 and RH domains were mutated to alanine, RIN3 interaction with Rab31, but not Rab5, was abolished. These residues are theoretically located between the PRDs and closely upstream to the RH domain. It is thus likely that the RH domain may provide specificity in substrate binding to VPS9 (Kajiho et al., 2011). Functionally speaking, it is possible that the RH region is required for interacting with Rab5 family members and the VPS9 domain is critical for its GEF activity of RIN proteins, thus deletion of either domain will abolish RIN GEF activity.

Despite all RIN family proteins are believed to catalyze the GDP/GTP exchange for the Rab5 family proteins (including Rab5A/B/C, Rab21, Rab 22, and Rab31), each member may show slight preference for different Rab5 family members. For example, RIN3 had relatively higher GEF activity towards Rab31 when compared to RIN1, 2 (Kajiho et al., 2011). In addition, some interesting differences also exist among the members of the Rab5 family that may reflect the heterogeneous nature of the early endosomal population; and each Rab5 family member may reside within a subpopulation of early endosomes. Because of its strong GEF activity towards Rab5, expression of exogenous RIN3 induced enlarged early endosomes, mediated by the early endosome antigen 1 (EEA1) (Simonsen et al., 1998). However, RIN3 showed a greater degree of colocalization on early endosomes with Rab5, than with EEA1 (Kajiho et al., 2003b). Interestingly, overexpressed RIN3 was found to be colocalized with Rab31, and RIN3/Rab31 exhibited partial overlap with EEA1, suggesting that RIN3/Rab31 were partially localized on EEA1-positive early endosomes (Kajiho et al., 2011). Furthermore, following internalization, transferrin was observed to stay within the RIN3/Rab5-positive vesicles for...
Upon EGF stimulation, activated EGFR promoted the
interacts with the ABL2 non-receptor tyrosine kinase, through
RIN3 another bridge for Ras-cell signaling and Rab5-endocytosis
and endocytic receptor mediated internalization, which makes
interaction or Ras induced RIN3 mediated endocytic alternation
relationship between Ras and RIN3 to date. Evidence for their
endosomes (Kajiho et al., 2003b). More detailed studies will be
endoendocytic transduction events with the endocytic process.
Deletion of the SH2 domain in each of the three RIN proteins
was used to evaluate its function. GEF activity increased after SH2
deletion in RIN1 and RIN2 compared to their full-length form
(Tall et al., 2001; Saito et al., 2002). RIN3 had reduced
colocalization with Rab5 after SH2 deletion (Yoshikawa et al.,
All these results point to a mechanism by which the SH2
domain may self-inhibit the GEF activity of RIN proteins. It is
possible that at the onset of activation, receptor tyrosine kinases
(RTKs) bind to the RIN SH2 domain(s) to suppress their GEF
activity and to facilitate signal transduction; inactivation of RTKs
by tyrosine phosphatase(s) then results in decoupling RTKs from
RIN SH2. As such, the GEF activity is disinhibited to initiate
endocytosis and endocytic traffic. Further efforts are needed to
test this hypothesis (Figure 3).

The Proline-Rich Domains
The number of PRDs is the most obvious difference between the RIN
proteins (one in RIN1, two in RIN2 and three in RIN3) (Figure 1).
PRD is a functionally important motif that can bind to multiple proteins via SH2 and SH3 domains. The "PxPxPR" sequence in two
of the three RIN3 PRDs was identified to be the key structure that
binds to two SH3 domains of the CD2-associated protein (CD2AP)
(Rouka et al., 2015). Similarly, the SH3 domain of bridging integrator
1, BIN1 (also known as amphiphysin I) interacted with the
N-terminal fragment (amino acids 1–586) of RIN3, that also
encompassed the three PRDs (Kajiho et al., 2003b). It is thus not
surprising that RIN3 recruited CD2AP and BIN1 to Rab5 positive
vesicles (Shen et al., 2020), but the impact of this interaction on the
RIN3 GEF activity and the cellular function of this complex is
unknown. In addition, BIN2 was found to interact with RIN3 in the
LAD2 human mast cell line (Janson et al., 2012). Given that BIN1
and BIN2 share both the analogous Bin1/amphiphysin/Rvs167 (BAR) and SH3 domain (Ren et al., 2006), it is likely that BIN2
also binds to the RIN3-PRD via its SH3 domain. The interaction of
RIN3 and BIN2 was diminished under stem cell factor (SCF)
stimulation but can be restored after recovery from the
stimulation for 4 h (Janson et al., 2012). These results suggests that
interaction between RIN3 and BIN1/BIN2 can also be
regulated by RTKs signaling.

Potential Self-Interaction
The PRDs (residues 207–496) of RIN2 also interact with full
length RIN2, while the VPS9-PRD domain (residues 642–895)
also showed positive but weak interaction (Saito et al., 2002). Both the N-terminal SH2 domain and the C-terminal RA domain of RIN2 displayed strong interaction with themselves, which suggest that two RIN2 molecules might form parallel complexes in a head-to-head and tail-to-tail configuration. Both the PRDs and the N-terminal region (207–297 amino acid residues between the SH2 and PRDs) were required to bind the C-terminal RH, VPS9 and RA domains. Thus, RIN2 might also form antiparallel complexes in a head-to-tail configuration. Alternately RIN2 can fold itself to accomplish self-interaction between its N- and C-terminal region (Saito et al., 2002). Given the sequence similarity among the RIN proteins, it is likely that RIN1 as well as RIN3 each possess some self-interaction ability. Although RIN3 dimerization, either in cell lines or in mouse brain samples, was not detected in a recent study (Shen et al., 2020), further structural analysis, biochemistry and cell biology studies are needed to fully clarify all these hypotheses and to define the function of these interactions.

**RIN3 AND HUMAN DISEASES**

RIN3 has been linked to multiple human diseases such as Paget’s Disease of bone (PDB), Alzheimer’s Disease (AD), Chronic Obstructive Pulmonary Disease (COPD), obesity, sickle cell disease etc. It is perhaps not surprising that all these diseases involve tissues or organs that have high expression of RIN3.

**RIN3 and Paget’s Disease of bone**

Paget’s Disease of bone (PDB) is the second most common metabolic bone disorder after osteoporosis. PDB patients suffer from a variety of symptoms ranging from softer bones to increased bone growth; The enlarged bone growth typically involves one or more bones of the pelvis, low back (spine), hips, thighs, head (skull) and arms. Although most patients are asymptomatic throughout the disease evolution, pain, bone deformity, pathological fracture and deafness are common clinical manifestations (Tan and Ralston, 2014). Increased bone turnover induces larger bone volume, such that patients often complain about enlarged feet or head because of abnormal bone thickening (Seitz et al., 2009). Osteoclasts are increased in both size and number, that may elevate osteolytic activity, leading to enhancement of bone formation (Roodman and Windle, 2005). Presently, there is no effective treatment for PDB except for pain control in clinic practice. The disease etiology and pathogenesis remains largely undefined (Alonso et al., 2017).

Genetic factors play an important role in PDB. 7–30% patients have positive family history with an autosomal dominant mode of transmission (Morales-Piga et al., 1995; Hocking et al., 2000; Hocking et al., 2001; Laurin et al., 2001). Mutations in Sequestosome 1 (SQSTM1)/p62 protein, a ubiquitin signaling and autophagy receptor, were first identified as a genetic cause of PDB (Hocking et al., 2002; Laurin et al., 2002).

Recent genome-wide associated studies (GWAS) have identified seven loci with robust association with PDB (Albagha et al., 2010; Albagha et al., 2011). Among them, rs10498635 C allele on chromosome 14q32.12 was strongly associated with PDB in several European populations (p-value = 2.55 × 10^{-11}, odds ratio OD = 1.44 (1.29–1.60). The region contains only the RIN3 gene and 62kb upstream of the RIN3 coding region. Through targeted sequencing of the 60kb region in the RIN3 gene in samples from 741 PDB patients and 2,699 healthy controls, Vallet et al. (Vallet et al., 2015) identified 18 PDB-associated variants in RIN3 including 16 missense variants. Among the 16 missense variants, 9 loci located in the PRDs, 1 in the SH2 domain and 3 in the VPS9 domain (Vallet et al., 2015).
Three missense variants are most common in PTB: the rs117068593 T allele, the rs117068593 C allele and the rs10498635 C allele. The rs117068593 T allele was carried by more individuals in the healthy control group than in the PDB group (OR = 0.68; 95% CI = 0.58–0.81; imputed \( p = 5.7 \times 10^{-6} \)). The rs117068593 C allele and the rs10498635 C allele both displayed strong linkage disequilibrium, indicating that these two variants may play a pathogenic role in PDB (Vallet et al., 2015). Many of the rare variants identified in this study were more common in the PDB cases than with the healthy controls. Although these variants did not reach statistical significance individually, the results were highly significant when they were combined (OR = 3.72; 95% CI = 2.38–5.82; \( p = 8.9 \times 10^{-10} \)) (Vallet et al., 2015).

22 distinct variants were recently identified in a Belgian population. Eight of them were newly recognized missense variants, and two were in the UTRs (De Ridder et al., 2019). The N terminal variant P16L was found only in one control individual. The W63C variant in the SH2 domain was found in two control individuals but not in any PDB patients, despite the fact this variant was predicted to be deleterious by all predictive tools. Interestingly, W63C was also identified to be a risk factor for sporadic early onset Alzheimer’s disease (sEOAD) (Kunkel et al., 2017). A series of rare variants (p.K689R, p.Y793H,
p.K838T and p.R859C) were exclusively found in patients and were all located in the RH and the VPS9 domain (Figure 4A). The P386S variant probably diminishes interaction between the PRDs and the SH3 domain (Rouka et al., 2015). Mutations in the SH2 domain (W63C and A141V) do not seem to disrupt interaction between the PRDs and the SH3 domain (Figure 4A).

Presently, the function of RIN3 in bone biology and homeostasis remains unknown. However, an intron variant rs754388 was found to associate with lower and upper limb bone mineral density (BMD), and this variant was in high linkage disequilibrium with common PDB variant rs117068593. This suggests a significant role for RIN3 in the regulation of bone mass development and maintenance of skeletal health (Kemp et al., 2014). Similar association between rs754388 and bone mineral density (BMD), a heritable, polygenic trait, was identified (Medina-Gomez et al., 2017).

As discussed earlier, RIN3, as a Rab5 GEF, regulates Rab5 GTPase to impact intracellular transport pathways. Rab GTPases have been strongly implicated in the regulation of osteoclast function and bone resorption (Ittzstein et al., 2011; Weivoda and Oursler, 2014). For instance, a mouse model that harbors a mutation in the catalytic subunit of the Rab geranylgeranyl transferase (RGGT) showed a loss of 75% of the activity of this enzyme and hence hypoprenylation of several Rabs (Rab2B, Rab3D, Rab5, Rab6, Rab7, and Rab14) in osteoclasts. Prenylation is required for these Rab proteins to associated with membranes; hypoprenylation may thus reduce membrane attachment and decrease the ability of Rabs, affecting intracellular transport pathways (Alexandrov et al., 1994; Goody et al., 2005). Although osteoclasts from the RGCT mice showed normal differentiation and polarization, they exhibited reduced resorptive activity in vitro (Taylor et al., 2011). Consistently, disruption of Rab geranylgeranylation with a phosphonocarboxylate inhibitor of RGGT inhibited osteoclast bone resorption (Coxon et al., 2001). Thus, deletious missense mutations found in RIN3 may disrupt Rab5 activity, that could result in osteoclast dysfunction.

Using a mouse model with a targeted inactivation of the mouse Rin3 gene, Vallet et al. (Vallet et al., 2021) showed that the homozygous RIN3 knock out (−/−) mice had normal weight compared to their wild type controls. However, micro-computer tomography (micro-CT) analysis revealed that, comparing to the wildtype control, the RIN3−/− mice showed a significant increase in bone mass and trabecular number, but a significant decrease in trabecular separation (Vallet et al., 2021). Although the number of osteoclasts in the trabecular bone remained unchanged in bone sections, the surface occupied by Tartrate-resistant acid phosphatase staining (TRAcP)-positive osteoclasts was significantly reduced in the RIN3−/− mice (Vallet et al., 2021). These results suggest that the RIN3−/− mice may have fewer active osteoclasts. It is thus likely that RIN3 deletion interferes with osteoclast activity and reduce bone resorption, thus leading to increased bone mass.

In summary, multiple mutations in RIN3 have been identified to associate with elevated risk of PDB. However, whether these mutations function as gain or loss of function to contribute to the pathogenesis of PDB remains unclear. Although some domains whose structures have been predicted with high precision by AlphaFold (Jumper et al., 2021; Varadi et al., 2021) (Figure 4B), also see Supplementary Movie S1), the 3D structure of RIN3 is far from being resolved. How the mutation(s) alters the structure and function of RIN3 in PDB and other conditions as discussed below will be hopefully answered in the future.

**RIN3 and Alzheimer’s Disease**

Alzheimer’s Disease (AD) is the most common progressive neurodegenerative disorder whose clinical manifestations included late memory loss and cognitive impairment (Selkoe and Hardy, 2016). The classical neuropathological hallmarks for AD include β-amyloid-containing neuritic plaques and phosphorylated Tau-containing neurofibrillary tangles (NFT) (Karch et al., 2014). In addition, significant synaptic loss, selective neuronal death, neurotransmitter defects and neuroinflammation are also observed in AD (Karch and Goate, 2015; Barragán Martínez et al., 2019).

Despite the tremendous efforts and investments in the past decades, there are currently no disease-modifying therapy for effective treatments of AD (Doody et al., 2013a; Doody et al., 2013b; Gauthier et al., 2016).

As a multifactorial disease, genetic background proves to play an important role in AD pathogenesis. In 2009, apolipoprotein E (APOE), which functions in lipid transport, Aβ traffic, synaptic function, immune regulation, and intracellular signaling (Mahley et al., 2008), was identified as a risk factor for late onset AD (LOAD) (Gatz et al., 2006). More recently, large scale GWAS and a meta-analysis of LOAD patients have identified more than 20 additional risk factors (Harold et al., 2009; Seshadri et al., 2010; Sherva et al., 2011; Chapuis et al., 2013). The identification of these additional risk factors further illustrates the extraordinary genetic complexity of AD.

A significant number of the newly identified loci (PICALM, BIN1, BIN1, CD2AP, MEF2C, PTK2B, SORL1 and RIN3) encode protein products with significant roles in endocytic traffic and signaling (Karch and Goate, 2015). The involvement of RIN3 in LOAD was revealed by the identification of a locus (rs10498633, G/T), upstream of the SC24A4 gene (Chapuis et al., 2013; Lombert et al., 2013). This single nucleotide polymorphism (SNP), also known as the SLC24A4/RIN3 SNP, was speculated to cause an increase in the expression of RIN3 in LOAD patients. When comparing extreme AD cases with centenarian controls, the variant effect size for the SLC24A4/RIN3 SNP increased by 4.5-fold, versus 2-fold for APOE-e4 and 6.5-fold for TREM2 (R74H) variant in comparison to published effect sizes (Tesi et al., 2019). Stage et al. (2016) used elegant brain imaging to analyze the effect of the top 20 AD risk genes on gray-matter density and FDG PET brain metabolism By analyzing a cohort of 381 normal controls, 634 mild cognitive impairment (MCI) patients and 243 dementia patients, they determined that the RIN3 risk variant rs10498633 G/T was significantly associated with mean median temporal lobe grey matter density (GMD) (Stage et al., 2016). The RIN3 variant was also a significant predictor of hypometabolism in normal control group (Stage et al., 2016).
In a recent study, PICALM (rs10792832), BIN1 (rs6733839), CD2AP (rs10948363), and RIN3 (rs10498633) were sequenced in a Danish cohort of 74,754 individuals from the general population (Juul Rasmussen et al., 2019). The results were used to generate a weighted and a simple allele score. The analysis has revealed that all four variants were associated with increased risk of AD and all other dementia cases including vascular dementia. Furthermore, the effect of these risk factors was independent of the strong APOE-ε4 allele (Juul Rasmussen et al., 2019).

A more recent case-control study of whole-exome sequencing of 93 patients with sporadic early onset AD (sEOAD) has discovered a missense Rin3 variant (rs150221413, G/T). The mutation results in a substitution of 63W > C in the SH2 domain of Rin3 (Kunkle et al., 2017). The Rin3W63C variant is strongly associated with sEOAD (OR, 4.56; 95% CI, 1.26–16.48; \( p = 0.02 \), BP = 0.091) (Kunkle et al., 2017). In an analysis of 624 Taiwanese people with an average age of 64.2 years, Lin and colleagues identified 11 Rin3 variants that were markedly correlated with the Mini-Mental State Examination (MMSE) score (\( p < 0.05 \)) (Lin et al., 2017). Among them, an intron-variant rs1885747 on Rin3 was found to be positively correlated with the MMSE score in the cohort (Lin et al., 2017), although it is not clear the effect of this variant on the expression of Rin3 presently.

The potential involvement of Rin3 in AD pathogenesis is also supported by epigenetic studies. In a 2017 study of gene methylation profiling of blood and brain samples from 22 AD and 26 normal control subjects (27 males, 21 females), the AD samples showed significant group-wide hypomethylation of 7 CpGs located within the 3′UTR region of Rin3 (Cpg1 \( p = 0.019 \), Cpg2 \( p = 0.018 \), Cpg3 \( p = 0.012 \), Cpg4 \( p = 0.009 \), Cpg5 \( p = 0.002 \), Cpg6 \( p = 0.018 \), and Cpg7 \( p = 0.013 \), respectively) (Boden et al., 2017). The effect was specific for Rin3 since other LOAD risk factors (PTK2β, ABCA7, SIRT1, or MEF2C) did not show significant changes in methylation of their respective promoters. Additionally, a genome wide methylation study of Mexican Americans with mild cognitive impairment uncovered significant hypo-methylation in Rin3 and three other genes (Pathak et al., 2019). Together, these studies have suggested the possibility that increased expression of wildtype Rin3 or expression of the Rin3 variant (W63C) may contribute to AD pathogenesis. However, the underlying mechanism(s) is presently unknown.

An important question is how dysregulation of Rin3 expression and function contributes to AD pathogenesis. Given that neurons have the most extraordinary architecture with elaborate dendrites/axons which undoubtedly impose a significant need for endocytic processes, it is not surprising that these early endocytic pathways are found to be dysregulated in AD (Cataldo et al., 2004; Ginsberg et al., 2010; Ginsberg et al., 2011; Nixon, 2005). Persistent hyperactivation of Rab5 was observed in early phases of AD (Ginsberg et al., 2010; Ginsberg et al., 2011; Kim et al., 2016; Xu et al., 2016). Under normal conditions, Rab5-early endosomes are a major site of APP processing by β-secretase (BACE1) to yield the β-cleavage C-terminal fragment (βCTF), which is further processed in late endosomes/trans-Golgi network (TGN) to give rise to A\( β \) (Cataldo et al., 2004; Kinoshita, 2003; Nixon, 2005; Thinakaran and Koo, 2008; Xu et al., 2016). Therefore, trafficking and processing of APP to produce toxic βCTFs/A\( β \) is intimately regulated by the endocytic pathways (Grbovic et al., 2003). Studies have demonstrated that neurotrophic factors such as nerve growth factor (NGF) and its receptor TrkA are engulfed into early endosomes and are retrogradely transported from the presynaptic terminal to soma (Figure 5). This process is vital for neuronal survival and function (Howe et al., 2001). It is the Rab5 positive vesicles that carry and move the trophic signaling complex in the process (Delcroix et al., 2003; Xu et al., 2016). Thus, dysregulation of Rab5 traffic may deprive neurons of vital survival signals that leads to neurite retrieval and degeneration (Laienfeld et al., 2007; Xu et al., 2016). Hence, increased expression level or elevated activity of Rin3 might account for the upregulation of Rab5 activation in these studies, potentially leading to axonal transport impairments (Figure 5).

In addition, we have recently demonstrated that Rin3 interacts with the SH3 domains of CD2AP and BIN1, two known LOAD risk factors (Shen et al., 2020). The tripartite Rin3/BIN1/CD2AP complex may play an important role in AD pathogenesis (Shen et al., 2020). Overexpression of Rin3 recruited CD2AP and BIN1 to Rab5 positive early endosomes (Shen et al., 2020). CD2AP, a membrane-associated scaffolding protein, likely controls the assembly of protein complexes and participates in endocytosis and endocytic traffic to transmit intracellular signals (Harrison et al., 2016). CD2AP, by virtue of its multiple protein-protein binding modules, interacts with multiple proteins involved in diverse biological processes (Harrison et al., 2016). A previous study has shown that suppression of CD2AP resulted in a decreased A\( β_{42}/Aβ_{40} \) ratio both in N2a neuron-like cell lines and in 1 month-old APP/PS1 mice (Liao et al., 2015). Additionally, deletion of CD2AP also decreased APP CTFs (Ubelmann et al., 2017). Together, these studies have suggested a role for CD2AP in amyloidogenesis.

The longest isoforms of BIN1, expressed predominantly in the central nervous system, contain a unique clathrin-AP2 binding region (CLAP) (Chapuis et al., 2013). Although the role of BIN1 in regulating APP processing is currently under debate (Calafate et al., 2016; Ubelmann et al., 2017; Crotti et al., 2019), BIN1 interacts with Tau (Calafate et al., 2016; De Rossi et al., 2016; Crotti et al., 2019), indicating its potential role in regulating Tau biology. This was confirmed in a recent study, which found that increased BIN1 expression disrupted eye morphology by modulating Tau pathology in Drosophila rather than A\( β_{42} \) pathology (Kingwell, 2013). Hence, Rin3 may act as a scaffold between CD2AP and BIN1: promoting amyloid pathology via CD2AP and enhancing tau pathology via BIN1.

Based on our current knowledge, we propose the following model to explain how dysregulation and dysfunction of Rin3 contributes to AD pathogenesis by impacting intracellular traffic of Rab5 early endosomes; Rin3 activates Rab5 to promote amyloidogenic processing of APP and tau phosphorylation. Specifically, we postulate that Rin3 forms a complex with BIN1 and CD2AP (Figure 6, step 1). Increased activity of Rin3 enhances Rab5 activation and induces the formation of
the RIN3-BIN1-CD2AP complex on early endosomes, that results in impaired endocytic trafficking (Figure 6, step 2,3). Therefore, RIN3-BIN1 stimulates GSK3β to induce tau phosphorylation (Figure 6, step 4, 5); on the other hand, impaired traffic results in processing of APP by BACE1 in early endosomes (Figure 6, step 6, 7).

Currently, the exact role played by the newly identified RIN3 W63C variant in eEOAD is not clear. This particular variant is predicted to be deleterious by multiple prediction tools (De Ridder et al., 2019). Since W63 is located in the beginning of the SH2 domain of RIN3, as discussed earlier, binding of the SH2 domain to phosphorylated tyrosine residues in TKs would suppress the GEF activity of RIN3. It is possible that the W63C mutation weakens the binding of SH2 domain to these phosphotyrosine residue targets and as such, the Rab5 GEF activity in RIN3 is dis-inhibited (Yoshikawa et al., 2008) (Figure 3). The W63C variant, in effect, would result in hyper-activation of Rab5 (Figure 3), which in turn, promotes APP processing and tau phosphorylation (Figure 6). Future studies will be needed to investigate this attractive hypothesis.

**RIN3 and Chronic Obstructive Pulmonary Disease**

Chronic Obstructive Pulmonary Disease (COPD) is a common pulmonary disease that is characterized by persistent airflow obstruction. The limitation on airflow is often progressive and associated with abnormal inflammation response of the lung to noxious particles or gases (Fabbri et al., 2003). The onset of the disease normally occurs in midlife and is strongly associated with tobacco smoking history. Patients present with complex pulmonary symptoms such as shortness of breath, wheezing, chronic cough, frequent respiratory infection, etc. Post bronchodilator lung function is used to diagnose and classify COPD. The pathological change in COPD is a mixture of small airway alteration, parenchymal destruction (emphysema), and, in many cases, increased airway responsiveness (asthma) (Fabbri et al., 2003). This disease can be largely preventable and treatable because multiple risk factors are related to smoking and air quality (Mannino and Buist, 2007).

However, patients with similar exposure to tobacco smoking can vary greatly in disease severity and their response to intervention, suggesting that individual genetic diversity may strongly impact the disease progression. Multiple GWAS analyses were performed and RIN3 was identified as a risk factor. In 2014, a genome-wide association case-control study of severe COPD was carried out; the results revealed that Rin3...
rs754388 allele C was a risk allele \( p = 5.25 \times 10^{-9}, \text{OR} = 1.28 \) (1.18–1.39) (Cho et al., 2014). A meta-analysis then found this variant to have a significant association with pulmonary FEV1/FVC function (Forced Expiratory Volume in 1 s/Forced Vital Capacity) (Lutz et al., 2015). In addition, another missense variant rs17068593 (R279C) was identified to be associated with pulmonary function FEV\(_1\) (Forced Expiratory Volume in 1 s) (Soler Artigas et al., 2015).

Perhaps it is not surprising that RIN3 mutation is associated with pulmonary disease due to its high expression level in the lung. However, two other RIN3 variants identified in this study are also associated with PDB and BMD (See discussion in RIN3 and Paget’s Disease of Bone), but not with AD. Although very little is known regarding RIN3 function in pulmonary tissue, small GTPases Rab5 and Rab7 are upregulated in alveolar macrophages (Subramaniam et al., 2016). The upregulation of Rab5 and 7 was impaired by second-hand cigarette smoke and this effect can be rescued with recombiant granulocyte–macrophage colony-stimulating factor (GM-CSF). These studies suggest that these Rab proteins may associate to damage repair process in tobacco induced pulmonary conditions (Subramaniam et al., 2016). Dysregulation of RIN3 may thus exacerbate the damages by tobacco in COPD.

**RIN3 and Metabolic Syndrome**

Obesity and metabolic syndrome (MetS) are crucial risk factors for cardiovascular disease, diabetes mellitus (DM), hypertension, etc. The heritability of obesity and MetS are respectively 40–70 and ~30%. Multiple GWAS have been conducted in different human populations and more than 100 loci have been identified. In 2017, an exome-wide association study (EWAS) in the Japanese population identified a new locus on Rin3, rs8018360, that was associated with obesity \( p = 6.79 \times 10^{-9}\). The rs8018360 can be either T or G, but the T allele was more commonly found in patients, thus defined as a risk allele (Yamada et al., 2017). This variant is located towards the end of the possible promoter region of Rin3. Its specific role in expression regulation or RNA splicing is still unknown.

Using next-generation RNA sequencing technology, Padilla and colleagues found that the Rin3 mRNA level in artery tissues was consistently downregulated in obese rats compared to normal rats (Padilla et al., 2014). Although the function of Rin3 in adipose tissue and metabolic pathways is unclear, its downstream Rab5 protein plays a role in these processes. Rab5 activity modulates transport of glucose transporter isoform 4 (GLUT4). Rab5 may also play a role in insulin resistance, a common phenomenon in obesity and MetS (Tessneer et al., 2014). It is thus possible that Rin3 regulates insulin signaling via the Rab5 endocytic pathway.

**CONCLUDING REMARKS**

RIN3, acts as a GEF for Rab5 to regulate endocytosis and endocytic traffic. By interacting with RAS via its RA domain or with RTKs via its SH2 domain, RIN3 also participates in multiple cellular signaling pathways. Recent evidence has suggested that dysfunction of RIN3 is associated with several human diseases such as Paget’s disease of bone, Alzheimer’s disease, chronic pulmonary obstructive disease and obesity. All disease associated-missense mutations are located in the functional domains and thus could alter the function of RIN3 protein. On the other hand, most Rin3 polymorphisms and variants are found in the noncoding regions (likely to be promoters or enhancers), which may impact the expression level of RIN3.

A significant issue that needs to be resolved is how the different mutations of RIN3 lead to or contribute to the pathogenesis of very different human diseases. Although we speculate that, through activation of Rab5, increased expression of Rin3 contributes to LOAD and the W63C variant to EOAD, it is far from clear if the same mechanism that also operates for other diseases. Given the role played by Rin3 in endocytic trafficking, it is plausible that specific mutations may alter Ca\(^{2+}\) metabolism that causes PDB; whereas in other cases, Rin3 missense mutations/variants affect reabsorption and repair of damaged lung tissues in COPD; Some other mutations may selectively affect cellular insulin signaling and trafficking in DM. Defining the cellular and signaling mechanisms by which the different mutations alter the cellular function of Rin3 will be critical to answer these important questions. Future studies are needed to focus on both defining the structure and delineating cellular interactomes of Rin3 under both physiological and pathological conditions. These efforts will generate insights into its role in disease pathogenesis and inform novel targets for developing effective therapies for these diseases.

**AUTHOR CONTRIBUTIONS**

RS, JD, CW conceived and wrote the manuscript; CJM, XX, MH helped with revising Figures.

**FUNDING**

The project was supported by UCSD ADRC P50 Pilot Grant (CW); the National Natural Science Foundation of China #81630029 and #81871005 (JD), the National Key R&D Program of China #2016YFC13060000 (JD).

**ACKNOWLEDGMENTS**

We thank the members of our laboratory for providing generous assistance.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2022.824961/full#supplementary-material
REFERENCES

Albagha, O. M., Wani, S. E., Visconti, M. R., Alonso, N., Goodman, K., Brandi, M. L., et al. (2011). Genome-wide Association Identifies Three New Susceptibility Loci for Paget’s Disease of Bone. *Nat. Genet.* 43, 685–689. doi:10.1038/ng.845

Albagha, O. M. E., Visconti, M. R., Alonso, N., Langston, A. L., Cundy, T., Dargie, R., et al. (2010). Genome-wide Association Study Identifies Variants at CSF1, OPTN and TNNFSF11A as Genetic Risk Factors for Paget’s Disease of Bone. *Nat. Genet.* 42, 520–524. doi:10.1038/ng.562

Alexandrov, K., Horuchi, H., Steele-Mortimer, O., Seabra, M. C., and Zerial, M. (1994). Rab Escort Protein 1 Is a Multifunctional Protein that Accompanies Newly Preynlated Rab Proteins to Their Target Membranes. *EMBO* J. 13, 5262–5273. doi:10.1002/1607-6167.1994.tb08606.x

Alonso, N., Calero-Paniagua, I., and Del Pino-Montes, J. (2017). Clinical and Genetic Advances in Paget’s Disease of Bone: a Review. *Clinic Rev. Bone Miner Metab.* 15, 37–48. doi:10.1016/s12018-016-9226-0

Artigas, M. S., Wain, L. V., Miller, S., Kheirallah, A. K., Huffman, J. E., Alexandrov, K., Horiuchi, H., Steele-Mortimer, O., Seabra, M. C., and Zerial, M. (2019). Methylation Pro

Martínez, J. (2019).

Coxon, F. P., Helfrich, M. H., Larijani, B., Muzylak, M., Dunford, J. E., Marshall, D., et al. (2004). The SRC Homology 2 Domain of RIN1 Mediates its Binding to the Epidermal Growth Factor Receptor and Regulates Receptor Endocytosis. *J. Biol. Chem.* 278, 32027–32036. doi:10.1074/jbc.m40324200

Barberi, M. A., Kong, C., Chen, P.-I., Horuchi, H., Steele-Mortimer, O., Seabra, M. C., and Zerial, M. (2003). The Early Endocytic Pathway. *Nat. Rev. Mol. Cell Biol.* 1016/j.neurobiolaging.2004.02.027

Terio, N. B., et al. (2003). Rab5-stimulated Up-regulation of the Endocytic Expoenyme in Mature Oligodendrocytes and Localization to white Matter Tracts. *Mol. Neurodegeneration.* doi:10.1186/1302-016-0214-1

Delcroix, J.-D., Valletta, J. S., Wu, C., Hunt, S. J., Kowal, A. S., and Mobley, W. C. (2003). NGF Signaling in Sensory Neurons. *Neuron* 39, 69–84. doi:10.1016/s0896-6273(03)00397-0

Delprato, A., and Lambright, D. G. (2007). Structural Basis for Rab GTpase Activation by VPS9 Domain Exchange Factors. *Nat. Struct. Mol. Biol.* 14, 406–412. doi:10.1038/nsmb1232

De Rossi, P., Boggs-Prevot, V., Clayton, B. L. L., Vasquez, J. R., Van Sanford, C., Andrew, R. J., et al. (2016). Predominant Expression of Alzheimer’s Disease-Associated BIN1 in Mature Oligodendrocytes and Localization to white Matter Tracts. *Mol. Neurodegeneration.* doi:10.1186/s1302-016-0214-1

Delcroix, J.-D., Valletta, J. S., Wu, C., Hunt, S. J., Kowal, A. S., and Mobley, W. C. (2003). NGF Signaling in Sensory Neurons. *Neuron* 39, 69–84. doi:10.1016/s0896-6273(03)00397-0

Doody, R. S., Aisen, P. S., and Iwatsubo, T. (2013a). Semagacestat for Treatment of Alzheimer’s Disease. *New Engl. J. Med.*

Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2013b). A Phase 3 Trial of Semagacestat for Treatment of Alzheimer’s Disease. *New Engl. J. Med.*

Esters, H., Alexandrov, K., Iakovenko, A., Ivanova, T., Thomá, N., Rybin, V., et al. (2011). Vps9 and DSS4: Proteins with Weak but Distinct Nucleotide-Exchange Activities for Rab proteins11Edited by J. Karn. J. Mol. Biol. 310, 141–156. doi:10.1016/j.jmb.2001.753

Fabbri, L. M., Hurd, S. S., and Committee, G. S. (2003). Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 Update. *Eur. Respir. J.* 22, 1–14. doi:10.1183/09031936.03.000370

Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., et al. (2014). Analysis of the Human Tissue-Specific Expression by Genome-wide Integration of Transcriptomics and Antibody-Based Proteomics. *Mol. Cell Proteomics.* 13, 397–406. doi:10.1074/mcp.m113.0350

Gatta, M., Reynolds, C. A., Fratiglioni, L., Johnsson, B., Mortimer, J. A., Berg, S., et al. (2006). Role of Genes and Environments for Explaining Alzheimer Disease. *Arch. Gen. Psychiatry.* doi:10.1001/archpsyc.63.2.168

Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardard, J. H., et al. (2016). Efficacy and Safety of Tau-Aggregation Inhibitor Therapy in Patients with Mild or Moderate Alzheimer’s Disease: a Randomised, Controlled, Double-Blind, Parallel-Arm Phase 3 Trial. *The Lancet.* doi:10.1016/s0140-6736(16)31275-2

Ginsberg, S. D., Allred, M. J., Counts, S. E., Cataldo, A. M., Neve, R. L., Jiang, Y., et al. (2010). Microarray Analysis of Hippocampal CA1 Neurons Implicates Early Endosomal Dysfunction during Alzheimer’s Disease Progression. *Biol. Psychiatry 68*, 885–893. doi:10.1016/j.biopsych.2009.12.001

Hanna, M., Hall, T. G., and Horvitz, D. H. (1989). Vps9p Is a Guanine Nucleotide Exchange Factor Involved in Vesicle-Mediated Vacuolar Protein Transport. *J. Biol. Chem.* 274, 15284–15291. doi:10.1074/jbc.274.21.15284

Han, L., Wong, D., Dhaka, A., Afar, D., White, M., Xie, W., et al. (1997). Protein Kinase C Inhibitors that Inhibit Cell Migration Inhibit Cell Migration and Induce Apoptosis in Rat Forebrain Neurons in Mild Cognitive Impairment and Alzheimer’s Disease. *J. Neuroonart.* doi:10.1016/j.jchemneu.2011.05.012

Doody, R. S., Rak, A., and Alexandrov, K. (2005). The Structural and Mechanistic Basis for Recycling of Rab Proteins between Membrane Compartments. *Cmls., Cel. Mol. Life Sci.* 62, 1657–1670. doi:10.1007/s00018-005-4486-8

Gribovic, O. M., Mathews, P. M., Jiang, Y., Schmidt, S. D., Dinakar, R., Summers, T. M., et al. (2003). Rab5-stimulated Up-Regulation of the Endocytic Pathway Increases Intracellular β-Cleaved Amyloid Precursor Protein Carboxyl-Terminal Fragment Levels and Aβ Production. *J. Biol. Chem.* 278, 31261–31268. doi:10.1074/jbc.m30422200

De Ridder, R., Boudin, E., Vandeweyer, G., Devoeœur, J.-P., Fransen, E., Mortier, G., et al. (2019). Genetic Variation in RIN3 in the Belgian Population Supports its Involvement in the Pathogenesis of Paget’s Disease of Bone and Modifies the Age of Onset. *Calcif. Tissue Int.* 104, 613–621. doi:10.1007/s0022-019-00530-3

De Rosi, P., Boggs-Prevot, V., Clayton, B. L. L., Vasquez, J. R., Van Sanford, C., Andrew, R. J., et al. (2016). Predominant Expression of Alzheimer’s Disease-Associated BIN1 in Mature Oligodendrocytes and Localization to white Matter Tracts. *Mol. Neurodegeneration.* doi:10.1186/s1302-016-0214-1

Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., et al. (2009). Genome-wide Association Study Identifies Variants at CLU and
Kajiho, H., Saito, K., Tsujita, K., Kontani, K., Araki, Y., Kurosu, H., et al. (2003b). Shen et al. RIN3 in Human Disease
Hocking, L., Slee, F., Haslam, S. I., Cundy, T., Nicholson, G., van Hul, W., et al. (2002). Domain-specific Mutations in Sequestosome 1 (SQSTM1) Cause Familial and Sporadic Paget’s Disease. Hum. Mol. Genet. 11, 2735–2739. doi:10.1093/hmg/11.22.2735
Hocking, L., Slee, F., Haslam, S. I., Cundy, T., Nicholson, G., van Hul, W., et al. (2000). Familial Paget’s Disease of Bone: Patterns of Inheritance and Frequency of Linkage to Chromosome 18q. Bone 26, 577–580. doi:10.1016/s8756-3282(00)00278-7
Horiiuchi, H., Lippé, R., McBride, H. M., Rubino, M., Woodman, P., Stenmark, H., et al. (1997). A Novel Rab5 GDP/GTP Exchange Factor Complexed to Rabaptin-5 Links Nucleotide Exchange to Effector Recruitment and Function. Cell 90, 1149–1159. doi:10.1016/s0092-8674(00)8308-3
Howng, C. L., Valletta, J. S., Rusnak, A. S., and Mobley, W. C. (2001). NGF Signaling from Clathrin-Coated Vesicles. Neuron 32, 801–814. doi:10.1016/s0896-6273(01)00526-8
Hu, H., Bliss, J. M., Wang, Y., and Colicelli, J. (2005). RIN1 Is an ABL Tyrosine Kinase Activator and a Regulator of Epithelial-Cell Adhesion and Migration. Curr. Biol. 15, 815–823. doi:10.1016/j.cub.2005.03.049
Iztiehn, C., Coxon, F. P., and Rogers, M. J. (2011). The Regulation of Osteoclast Function and Bone Resorption by Small GTPases. Small GTPases 2, 117–130. doi:10.4161/gtp.2.3.16453
Janson, C., Kasahara, N., Prendergast, G. C., and Colicelli, J. (2012). RIN3 Is a Negative Regulator of Mast Cell Responses to SCF. PLoS One 7, e94615. doi:10.1371/journal.pone.0094615
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2017). Bivariate Genome-wide Association Meta-Analysis of Pediatric Osteopetrosis. J. Bone Miner Res. 33, 4259–4274. doi:10.1002/jbmr.3282
Juul Rasmussen, I., Tybjærg-Hansen, A., Rasmussen, K. L., Nordestgaard, B. G., Laurin, N., Brown, J. P., Morrisette, J., and Raymond, V. (2002). Recurrent Mutation of the Gene Encoding Sequestosome 1 (SQSTM1/p62) in Paget Disease of Bone. Am. J. Hum. Genet. 70, 1582–1588. doi:10.1086/340731
Liao, F., Jiang, H., Srivatsan, S., Xiao, Q., Lepton, K. B., Yamada, K., et al. (2015). Effects of CD2-Associated Protein Deficiency on Amyloid-β in Neuroblastoma Cells and in an APP Transgenic Mouse Model. Mol. Neurodegeneration 10. doi:10.1186/s13024-015-0069-y
Lin, E., Tsai, S.-J., Kuo, P.-H., Liu, Y.-L., Yang, A. C., and Kao, C.-F. (2017). Association and Interaction Effects of Alzheimer’s Disease-Associated Genes and Lifestyle on Cognitive Aging in Older Adults in a Taiwanese Population. Oncotarget 8, 24077–24087. doi:10.18632/oncotarget.15269
Lutz, S. M., Cho, M. H., Cho, M. H., Young, K., Hersh, C. P., Castaldi, P. J., et al. (2015). A Genome-wide Association Study Identifies Risk Loci for Spirometric Measures Among Smokers of European and African Ancestry. BMC Genet. 16, 138. doi:10.1186/s12863-015-0299-4
Malhey, R. W., Weisgraber, K. H., and Huang, Y. (2008). Apolipoprotein E: Structure Determines Function, from Atherosclerosis to Alzheimer’s Disease to AIDS. J. Lipid Res. 49, 694–707. doi:10.1194/jr0110841
Mannino, D. M., and Buist, A. S. (2007). Global burden of COPD: Risk Factors, Prevalence, and Future Trends. The Lancet 370, 765–773. doi:10.1016/s0140-6736(07)61380-4
Medina-Gomez, C., Kemp, J. P., Dimou, N. L., Kreiner, E., Chesi, A., Zemel, B. S., et al. (2017). Bivariate Genome-wide Association Meta-Analysis of Pediatric Musculoskeletal Traits Reveals Pleiotropic Effects at the SREBF1/TOM1L2 Locus. Nat. Commun. 8, 121. doi:10.1038/s41467-017-00108-3
Morales-Piga, A. A., Rey-Rey, J. S., Corres-González, I., Garcia-Sagredo, J. M., and López-Abente, G. (1995). Frequency and Characteristics of Familial Aggregation of Paget’s Disease of Bone. J. Bone Miner Res. 10, 663–670. doi:10.1002/jbmr.5650100421
Nixon, R. A. (2005). Endosome Function and Dysfunction in Alzheimer’s Disease and Other Neurodegenerative Diseases. Neurobiol. Aging. doi:10.1016/j.neurobiaging.2004.09.018
Otomu, A., Hadano, S., Okada, T., Mizumura, H., Kunita, R., Nishijima, H., et al. (2003). ALS2, a Novel Guaanine Nucleotide Exchange Factor for the Small GTPase Rab5, Is Implicated in Endosomal Dynamics. Hum. Mol. Genet. 12, 1671–1687. doi:10.1093/hmg/ddg184
Padilla, I., Jenkins, N. T., Thorne, P. K., Martin, J. S., Rector, R. S., Davis, J. W., et al. (2014). Identification of Genes Whose Expression Is Altered by Obesity throughout the Arterial Tree. Physiol. Genomics 46, 821–832. doi:10.1152/physiolgenomics.00091.2014
Pathak, G. A. S., Talisa, K., Sun, J., Zhou, Z., Daniel, A. A., Johnson, L., et al. (2019). Genome-Wide Methylation of Mild Cognitive Impairment in Mexican Americans Highlights Genes Involved in Synaptic Transport, Alzheimer’s...
Tall, G. G., Barbieri, M. A., Stahl, P. D., and Horazdovsky, B. F. (2001). Ras-Tesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N., Simister, P. C., Janning, M., Kumbrink, J., Konstantinou, T., Muniz, J. R., Roodman, G. D., and Windle, J. J. (2005). Paget Disease of Bone.

Pawson, T., Gish, G. D., and Nash, P. (2001). SH2 Domains, Interaction Modules and Schlessinger, J., and Lemmon, M. A. (2003). SH2 and PTB Domains in Tyrosine Kinase Signal. Sci. STKE 2003, Re12. doi:10.1126/scstke.2003.191.re12

Seitz, S., Priemel, M., Zustin, J., Beil, F. T., Semler, J., Minne, H., et al. (2009). Impaired Prenylation of Rab GTPases in Thegunmetalmouse Causes Defects in Bone Cell Function. PLoS ONE 4, e5292. doi:10.1371/journal.pone.0005292

Selkoe, D. J., and Hardy, J. (2016). The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years. EMBO Mol. Med. 8, 15252–15292. doi:10.15252/emmm.201606210

Seshadri, S., Fitzpatrick, A. L., Ikram, M. A., DeStefano, A. L., Gudnason, V., Boada, J. M., et al. (2011). Genome-wide Analysis of Genetic Loci Associated with Alzheimer Disease. JAMA - J. Am. Med. Assoc. 306, 244–252. doi:10.1001/jama.2011.574

Shen, R., Zhao, X., He, L., Ding, Y., Xu, W., Lin, S., et al. (2020). Upregulation of RIN3 Induces Endosomal Dysfunction in Alzheimer’s Disease. Transl Neurodegener 9, 26. doi:10.1186/s40035-020-00206-1

Sherva, R., Baldwin, C. T., Inzelberg, R., Vardarajan, B., Cupples, L. A., Lunetta, K., et al. (2016). The Effect of the Top 20 Alzheimer Disease Risk Genes on gray-matter Fusion. EMBO Mol. Med. 8, 73–89. doi:10.15252/emmm.201504328

Shams, H. (2016). Restoring Cigarette Smoke-Induced Impairment of Efferocytosis in Alveolar Macrophages. Respir Res. 17, 142. doi:10.4161/sgtp.2.3.16488

Tesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N., et al. (2019). Centenarian Controls Increase Variant Effect Sizes by an Average Twofold in an Extreme Case-Extreme Control Analysis of Alzheimer’s Disease. Eur. J. Hum. Genet. 27, 244–253. doi:10.1038/s41431-018-0273-5

Tessner, K. L., Jackson, R. M., Griessel, B. A., and Olson, A. L. (2014). Rab5 Activity Regulates GLUT4 Sorting into Insulin-Responsive and Non-insulin-responsive Endosomal Compartments: a Potential Mechanism for Development of Insulin Resistance. Endocrinology 155, 3315–3328. doi:10.1210/en.2013-2148

Thinakaran, G., and Koo, E. H. (2008). Amyloid Precursor Protein Trafficking, Processing, and Function. J. Biol. Chem. doi:10.1074/jbc.r008019200

Ubelmann, F., Burrinha, T., Salavessa, L., Gomes, R., Ferreira, C., Moreno, N., et al. (2017). Bin1 and CD 2 AP Polarise the Endocytic Generation of Beta-amyloid. EMBO Rep. 18, 102–112. doi:10.15252/embr.201642738

Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., et al. (2021). Proteomics. Tissue-Based Map of the Human Proteome. Science 347, 1206419.

Vallet, M., Soares, D. C., Wani, S., Sophocleous, A., Warner, J., Salter, D. M., et al. (2015). Targeted Sequencing of the Paget’s Disease Associated 14q32 Locus Identifies Several Missense Coding Variants in RIN3 that Predispose to Paget’s Disease of Bone. Hum. Mol. Genet. 24, 3286–3295. doi:10.1093/hmg/ddv068

Vallet, M., Sophocleous, A., Törnqvist, A. E., Azfer, A., Hof, R. v. t., Albagha, O. M., et al. (2021). Targeted Inactivation of Rin3 Increases Trabecular Bone Mass by Reducing Bone Resorption and favouring Bone Formation. Calcif Tissue Int. 109, 92–102. doi:10.1007/s00223-021-00827-2

Varadì, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., et al. (2021). AlphaFold Protein Structure Database: Massively Expanding the Structural Coverage of Protein-Sequence Space with High-Accuracy Models. Nature Cell Biol. 23, 1832–1840. doi:10.1038/s41556-021-00570-x

Weiwoda, M. M., and Oursler, M. J. (2014). The Roles of Small GTPases in Osteoclast Biology. Orthop. Muscular Syst. 3. doi:10.4172/2161-0533.1000161

Woller, B., Luiskandl, S., Popovic, M., Prierl, B. E. M., Ikonge, G., Mutl, M., et al. (2011). Rin-like, a Novel Regulator of Endocytosis, Acts as Guanine Nucleotide Exchange Factor for Rab5a and Rab22. Biochim. Biophys. Acta (Bba) - Mol. Cell Res. 1813, 1198–1210. doi:10.1016/j.jmb.2011.03.005

Xu, W., Weissmiller, A. M., White, J. A., 2nd, Fang, F., Wang, X., Wu, Y., et al. (2016). Amyloid Precursor Protein-Mediated Endocytic Pathway Disruption Induces Axonal Dysfunction and Neurodegeneration. J. Clin. Invest. 126, 1815–1833. doi:10.1172/jci82409

Yamada, Y., Sakuma, J., Takeuchi, I., Yasaki, Y., Kato, K., Oguri, M., et al. (2017). Identification of Rs7350481 at Chromosome 11q23.3 as a Novel Susceptibility Locus for Metabolic Syndrome in Japanese Individuals by an Exome-wide Association Study. Oncotarget 8, 39296–39308. doi:10.18632/oncotarget.16945

Yoshikawa, M., Kajiho, H., Sakurai, K., Minoda, T., Nakagawa, S., Kontani, K., et al. (2008). Tyr-phosphorylation Signals Translocate RIN3, the Small GTPase Rab5-GEF, to Early Endocytic Vesicles. Biochem. Biophysical Res. Commun. 372, 168–172. doi:10.1016/j.bbrc.2008.05.027

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Shen, Murphy, Xu, Hu, Dong and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.